E. Jane Byrne

9.1k total citations · 1 hit paper
52 papers, 3.1k citations indexed

About

E. Jane Byrne is a scholar working on Psychiatry and Mental health, Neurology and Physiology. According to data from OpenAlex, E. Jane Byrne has authored 52 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 18 papers in Neurology and 13 papers in Physiology. Recurrent topics in E. Jane Byrne's work include Dementia and Cognitive Impairment Research (20 papers), Parkinson's Disease Mechanisms and Treatments (14 papers) and Alzheimer's disease research and treatments (8 papers). E. Jane Byrne is often cited by papers focused on Dementia and Cognitive Impairment Research (20 papers), Parkinson's Disease Mechanisms and Treatments (14 papers) and Alzheimer's disease research and treatments (8 papers). E. Jane Byrne collaborates with scholars based in United Kingdom, Netherlands and France. E. Jane Byrne's co-authors include Alistair Burns, James Lowe, Graham Lennox, Iracema Leroi, R B Godwin-Austen, Sibel Tekin, Peter Quarg, Andrew Lees, Alberto Albanese and Dag Aarsland and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The British Journal of Psychiatry.

In The Last Decade

E. Jane Byrne

50 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rivastigmine for Dementia Associated with Parkinson's Disease

2004 793 citations Murat Emre, Dag Aarsland et al. New England Journal of Medicine profile →

Peers

E. Jane Byrne

NEURO

PMH

PHYSI

CN

PHARM

Sibel Tekin United States

Secundino López‐Pousa Spain

Florence Lebert France

Julia Zaccai United Kingdom

Ming Tang United States

Anette Lolk Denmark

Byron Creese United Kingdom

Uwe Ehrt Norway

H. Soininen Finland

J. M. Martínez‐Lage Spain

Sibel Tekin United States

E. Jane Byrne

1.4k ×1.0

NEURO

1.7k ×1.3

PMH

889 ×1.3

PHYSI

1.1k ×2.6

CN

454 ×1.3

PHARM

Citations per year, relative to E. Jane Byrne E. Jane Byrne (= 1×) peers Sibel Tekin

Countries citing papers authored by E. Jane Byrne

Since Specialization

Citations

This map shows the geographic impact of E. Jane Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Jane Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Jane Byrne more than expected).

Fields of papers citing papers by E. Jane Byrne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Jane Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Jane Byrne. The network helps show where E. Jane Byrne may publish in the future.

Co-authorship network of co-authors of E. Jane Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of E. Jane Byrne. A scholar is included among the top collaborators of E. Jane Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Jane Byrne. E. Jane Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Prendergast, Andrew J., et al.. (2023). 172 Using the early identification and management of delirium to optimise memory pathway referrals and resources. Age and Ageing. 52(Supplement_3).

2.

Leroi, Iracema, Michelle Andrews, Kathryn McDonald, et al.. (2011). Apathy and impulse control disorders in Parkinson’s disease: A direct comparison. Parkinsonism & Related Disorders. 18(2). 198–203. 57 indexed citations

3.

Leroi, Iracema, et al.. (2010). A pilot randomized controlled trial of sleep therapy in Parkinson's disease: effect on patients and caregivers. International Journal of Geriatric Psychiatry. 25(10). 1073–1079. 24 indexed citations

4.

Leroi, Iracema, et al.. (2009). Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Movement Disorders. 24(8). 1217–1221. 96 indexed citations

5.

Byrne, E. Jane, Michel Benoît, Yves Rolland, et al.. (2008). For whom and for what the definition of severe dementia is useful an edcon consensus. The journal of nutrition health & aging. 12(10). 714–719. 7 indexed citations

6.

Robert, Philippe, Frans R.J. Verhey, E. Jane Byrne, et al.. (2005). Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. European Psychiatry. 20(7). 490–496. 156 indexed citations

7.

Karim, Salman & E. Jane Byrne. (2005). Treatment of psychosis in elderly people. Advances in Psychiatric Treatment. 11(4). 286–296. 25 indexed citations

8.

Emre, Murat, Dag Aarsland, Alberto Albanese, et al.. (2004). Rivastigmine for Dementia Associated with Parkinson's Disease. New England Journal of Medicine. 351(24). 2509–2518. 793 indexed citations breakdown →

9.

Burns, Alistair, E. Jane Byrne, & Konrad Maurer. (2002). Alzheimer's disease. The Lancet. 360(9327). 163–165. 59 indexed citations

10.

Byrne, E. Jane, et al.. (2001). Dementia With Lewy Bodies Treated With Rivastigmine: Effects on Cognition, Neuropsychiatrie Symptoms, and Sleep. International Psychogeriatrics. 13(3). 277–288. 64 indexed citations

11.

Grace, Janet, Zuzana Walker, E. Jane Byrne, et al.. (2001). Long-Term Use of Rivastigmine in Patients With Dementia With Lewy Bodies: An Open-Label Trial. International Psychogeriatrics. 13(2). 199–205. 99 indexed citations

12.

McKeith, Ian G., Janet Grace, Zuzana Walker, et al.. (2000). Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. International Journal of Geriatric Psychiatry. 15(5). 387–392. 110 indexed citations

13.

Dennis, Michael, et al.. (1998). Clinical Associations of Lymphopenia in Elderly Persons Admitted to Acute Medical and Psychiatric Wards. Gerontology. 44(3). 168–171. 8 indexed citations

14.

Byrne, E. Jane. (1994). Confusional States in Older People. 7 indexed citations

15.

Morgan, Kevin, Jeanette Hofmann, Tom Arie, et al.. (1993). Incidence of Dementia in a Representative British Sample. The British Journal of Psychiatry. 163(4). 467–470. 35 indexed citations

16.

Byrne, E. Jane, et al.. (1992). Diagnosis of dementia. II—Diagnostic methods: A survey of current consultant practice and review of the literature. International Journal of Geriatric Psychiatry. 7(5). 323–329. 2 indexed citations

17.

Byrne, E. Jane. (1990). Neurological Complications of Systemic-Disease. UCL Discovery (University College London).

18.

Byrne, E. Jane & Tom Arie. (1990). Are drugs targeted at Alzheimer's disease useful? 2. Insufficient evidence of worthwhile benefit.. BMJ. 300(6732). 1132–1131. 3 indexed citations

19.

Morgan, Kàren, Helen Dallosso, Tom Arie, et al.. (1987). Mental Health and Psychological Well-being Among the Old and the Very Old Living at Home. The British Journal of Psychiatry. 150(6). 801–807. 119 indexed citations

20.

Byrne, E. Jane, et al.. (1978). Changing Mortality from Ischemic Heart-Disease and Acute Myocardial-Infarction. UCL Discovery (University College London). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact